Total Body Irradiation (TBI) by Adam Melancon by Adam Melancon - - PowerPoint PPT Presentation

total body irradiation tbi
SMART_READER_LITE
LIVE PREVIEW

Total Body Irradiation (TBI) by Adam Melancon by Adam Melancon - - PowerPoint PPT Presentation

Total Body Irradiation (TBI) by Adam Melancon by Adam Melancon April 9, 2015 April 9, 2015 Special Procedures at MDACC (June 2014) FY10 FY11 FY12 FY13 FY14 FY10 FY11 FY12 FY13 FY14 GK GK 442 459


slide-1
SLIDE 1

Total Body Irradiation (TBI)

by Adam Melancon April 9, 2015 by Adam Melancon April 9, 2015

slide-2
SLIDE 2

Special Procedures at MDACC (June 2014)

  • GK
  • Total Body
  • Total Skin
  • IORT
  • GK
  • Total Body
  • Total Skin
  • IORT

442 459 457 479 ? 37 43 49 74 39 to date 17 13 26 25 20 to date 30 26 58 12 ? 442 459 457 479 ? 37 43 49 74 39 to date 17 13 26 25 20 to date 30 26 58 12 ?

FY10 FY11 FY12 FY13 FY14 FY10 FY11 FY12 FY13 FY14

slide-3
SLIDE 3

Total Body Irradiation (TBI)

  • Clinical Basis For TBI
  • AAPM Report 17 (Task Group 25)

Recommendations

  • Current MD Anderson Technique
  • Clinical Basis For TBI
  • AAPM Report 17 (Task Group 25)

Recommendations

  • Current MD Anderson Technique
slide-4
SLIDE 4

Primary Purposes of TBI

  • Immunosuppression :

–For BMT (To kill lymphocyte cells to allow engraftment of donor stem cells)

  • Cytoreduction:

–Eradication of malignant cells (Leukemias, Lymphomas, etc) –Eradication of cell populations with genetic disorders (Fanconi’s anemia)

  • Immunosuppression :

–For BMT (To kill lymphocyte cells to allow engraftment of donor stem cells)

  • Cytoreduction:

–Eradication of malignant cells (Leukemias, Lymphomas, etc) –Eradication of cell populations with genetic disorders (Fanconi’s anemia)

slide-5
SLIDE 5

Uses of Total Body Irradiation

High Dose TBI

  • To destroy host’s bone marrow and kill

residual cancer cells

  • To immunosuppress pt prior to Bone

Marrow Transplant (BMT)

  • Usually adjuvant Chemotherapy +/- TBI

prior to BMT transplant

High Dose TBI

  • To destroy host’s bone marrow and kill

residual cancer cells

  • To immunosuppress pt prior to Bone

Marrow Transplant (BMT)

  • Usually adjuvant Chemotherapy +/- TBI

prior to BMT transplant

slide-6
SLIDE 6

Uses of Total Body Irradiation

High Dose TBI Tx regimen:

 4 – 10 Gy Single fraction (LD50 ~ 4 Gy)  6 Gy 3 Gy x 2, BID  10 – 14 Gy Fractionated 12 Gy in 1.5 Gy x 8 fx BID or 2~3 Gy daily fx 14 Gy in 1.75 Gy x 8 fx BID 12 Gy in 2.0 Gy x 6 fx BID (Europe)

Dose Rate : Between 5 and 25 cGy/min

High Dose TBI Tx regimen:

 4 – 10 Gy Single fraction (LD50 ~ 4 Gy)  6 Gy 3 Gy x 2, BID  10 – 14 Gy Fractionated 12 Gy in 1.5 Gy x 8 fx BID or 2~3 Gy daily fx 14 Gy in 1.75 Gy x 8 fx BID 12 Gy in 2.0 Gy x 6 fx BID (Europe)

Dose Rate : Between 5 and 25 cGy/min

slide-7
SLIDE 7

Uses of Total Body Irradiation

High Dose TBI :

  • Unlike most other treatment delivered by

a radiation oncologist, high-dose TBI is potentially lethal without intensive medical support and stem cell backup.

  • Incorrectly delivered TBI may result in

fatal toxicity as well. High Dose TBI :

  • Unlike most other treatment delivered by

a radiation oncologist, high-dose TBI is potentially lethal without intensive medical support and stem cell backup.

  • Incorrectly delivered TBI may result in

fatal toxicity as well.

slide-8
SLIDE 8

Clinical Complications - Sequelae

High Dose TBI

Lung Toxicity is most concerned Early Side effects: Nausea, Vomiting, Diarrrhea Within 10 days - Dry mouth, sore throat, reduced tear formation Hepatic enlargement, gonad failure, poor renal function Single fraction ~ 26% pt pop: interstitial pneumonitis may be avoided using fractionation Cataract formation (85% / 11 years) Risk of re-development of second tumor (chemo- irradiation + BMT) ~ 20%

High Dose TBI

Lung Toxicity is most concerned Early Side effects: Nausea, Vomiting, Diarrrhea Within 10 days - Dry mouth, sore throat, reduced tear formation Hepatic enlargement, gonad failure, poor renal function Single fraction ~ 26% pt pop: interstitial pneumonitis may be avoided using fractionation Cataract formation (85% / 11 years) Risk of re-development of second tumor (chemo- irradiation + BMT) ~ 20%

slide-9
SLIDE 9

Uses of Total Body Irradiation

Low Dose TBI

Why : To reduce risk and serious complications For : Lymphocytic Leukemia, Lymphomas, and Neuroblastoma Dose : 10–15 cGy/day for 10–15 days 2 Gy single fraction

Low Dose TBI

Why : To reduce risk and serious complications For : Lymphocytic Leukemia, Lymphomas, and Neuroblastoma Dose : 10–15 cGy/day for 10–15 days 2 Gy single fraction

slide-10
SLIDE 10

Low Dose TBI

  • Recently, a single fraction low-dose TBI (2 Gy)

combined with various chemotherapy regimens has emerged as an effective form of immuno- suppression prior to allogenic stem cell transplantation in non-myeloablative approaches.

  • Some trials reported only minor acute treatment-

related toxicities and faster hematopoietic engraftment.

  • Recently, a single fraction low-dose TBI (2 Gy)

combined with various chemotherapy regimens has emerged as an effective form of immuno- suppression prior to allogenic stem cell transplantation in non-myeloablative approaches.

  • Some trials reported only minor acute treatment-

related toxicities and faster hematopoietic engraftment.

slide-11
SLIDE 11

MDACC cases from Jan-June 2014

  • 37 pts received TBI, including 18 pedi and 19 adults
  • Adults Prescription

– 2.0 Gy x 1 (18 cases) – 3.0 Gy x 4 (1 case)

  • Pedi Prescription:

– 1.50 Gy x 8 BID (5 cases) – 1.65 Gy x 8 BID (1 case) – 1.75 Gy x 8 BID (5 cases) – 3 Gy x 2, 2Gy x 2, 4Gy x 2 – 2Gy x 1, 3Gy x 1, 4.50 Gy x 1

  • Dependent on transplant protocols and patient

conditions (lung, kidney, heart functions)

  • 37 pts received TBI, including 18 pedi and 19 adults
  • Adults Prescription

– 2.0 Gy x 1 (18 cases) – 3.0 Gy x 4 (1 case)

  • Pedi Prescription:

– 1.50 Gy x 8 BID (5 cases) – 1.65 Gy x 8 BID (1 case) – 1.75 Gy x 8 BID (5 cases) – 3 Gy x 2, 2Gy x 2, 4Gy x 2 – 2Gy x 1, 3Gy x 1, 4.50 Gy x 1

  • Dependent on transplant protocols and patient

conditions (lung, kidney, heart functions)

slide-12
SLIDE 12

State of the Art — 1938

Heublin ~1932, USA

Lead lined ward, 4 beds at one end, Coolidge tube at other end Beds 5 and 7m from tube Tx all 4 pts at one time! 20 Hrs, 185Kvp, 3mA, 2mm Cu 0.68 ~ 1.26 R/Hr as a % of erythema dose. (Bird cage!)

slide-13
SLIDE 13

State of the Art? – 2000

Shielded treatment room 4 - 18 MV beams Bed 4 to 5m from target One patient a time Custom blocks/bolus/MU Uniform Dose (±10%?)

slide-14
SLIDE 14

State of the Art? – 2000

Typical Rx Note: BID with 6 hrs apart Setup Note:

  • 1. SAD 380 cm
  • 2. Lucite scatter plate
  • 3. Rice bags at neck
  • 4. Dose rate 300 mu/min
  • 5. Lung blocks 4,6,8 fx
  • 6. Dose calc to midplane

level of umbilicus

slide-15
SLIDE 15

Purpose of AAPM Report #17

  • Review methods for producing large fields for TBI,

HBI, and other large field procedures

  • Make recommendations regarding dosimetric

measurements required for large fields

  • Consider the practical problems of specifying and

delivering radiation doses for such large fields

–Cost vs Benefit –Small enough room to minimize cost + Shielding + space –Simple procedure fewer sources

  • Review methods for producing large fields for TBI,

HBI, and other large field procedures

  • Make recommendations regarding dosimetric

measurements required for large fields

  • Consider the practical problems of specifying and

delivering radiation doses for such large fields

–Cost vs Benefit –Small enough room to minimize cost + Shielding + space –Simple procedure fewer sources

slide-16
SLIDE 16

TBI Methods

AAPM Report 17, figure 1.

four sources two horizontal beams single source, short SSD two vertical beams head rotation

slide-17
SLIDE 17

half body, adjacent direct fields

TBI Methods

AAPM Report 17, figure 1.

single source, long SSD source moves horizontally patient moves horizontally half body, direct and oblique fields

slide-18
SLIDE 18

Parallel-opposed Lateral Fields

slide-19
SLIDE 19

Dose Homogeneity AAPM Report 17, figure 2.

A=AP B=Lats

slide-20
SLIDE 20

Possible Dose Homogeneity

AAPM Report 17, figure 2.

  • The ratio of peak dose to midline dose decreases:

– As patient thickness decreases – With increasing beam energy – With increasing SSD

  • This implies better techniques use High energy, long SSD, and AP-

PA beam orientations.

  • If High Energies are used, consideration must be given to effects of

low doses in BU (buildup) region. Dose in BU may be increased by adding a beam spoiler (plastic plate) near pt skin.

  • The ratio of peak dose to midline dose decreases:

– As patient thickness decreases – With increasing beam energy – With increasing SSD

  • This implies better techniques use High energy, long SSD, and AP-

PA beam orientations.

  • If High Energies are used, consideration must be given to effects of

low doses in BU (buildup) region. Dose in BU may be increased by adding a beam spoiler (plastic plate) near pt skin.

slide-21
SLIDE 21

TBI Dose Distributions

  • AAPM Report 17,

Figure 9, 60Co parallel

  • pposed beams
  • ±10% dose uniformity

is possible for AP-PA beam orientation only

  • AAPM Report 17,

Figure 9, 60Co parallel

  • pposed beams
  • ±10% dose uniformity

is possible for AP-PA beam orientation only

Ext Contour Correction Pt water equivalent

Bolus

slide-22
SLIDE 22

TBI Dose Distributions

  • AAPM Report 17,

Figure 10, 25 MV parallel opposed beams

  • ±10% uniformity is

possible for both lateral and AP-PA beam orientations

  • AAPM Report 17,

Figure 10, 25 MV parallel opposed beams

  • ±10% uniformity is

possible for both lateral and AP-PA beam orientations

slide-23
SLIDE 23

Boosting Skin Dose

slide-24
SLIDE 24

Summary—Choice of Energy & SSD

  • Preferred

–Higher energy –Longer SSD –AP/PA beam orientation –Scatter plate close to the patient

  • Preferred

–Higher energy –Longer SSD –AP/PA beam orientation –Scatter plate close to the patient

slide-25
SLIDE 25

Basic Phantom Dosimetry

  • Water is the material of choice

–Plastic phantom need corrections to convert to water dose

  • Minimum size, 30x30x30 cm3

–Larger size preferred, use additional buildup material

  • Need to correct for lack of full scatter

–Depends on phantom size, field size and energy

  • Dosimeter should be energy

independent

  • Stem and cable effects should be

minimized

  • Water is the material of choice

–Plastic phantom need corrections to convert to water dose

  • Minimum size, 30x30x30 cm3

–Larger size preferred, use additional buildup material

  • Need to correct for lack of full scatter

–Depends on phantom size, field size and energy

  • Dosimeter should be energy

independent

  • Stem and cable effects should be

minimized

slide-26
SLIDE 26

Lateral Fields—Compensators

MDACC Technique(s)

Classic Technique Chair Technique Pediatric Technique

slide-27
SLIDE 27

MDACC TBI AP/PA “Classic Technique”

380 cm SAD 40  40 cm collimator 45°, Gantry 90° scatter plate Midline Laser Umbilicus 380 cm SAD Umbilicus Varian 2108 18MV

AP view PA view

slide-28
SLIDE 28

MDACC TBI Setup

slide-29
SLIDE 29

MDACC TBI Setup

slide-30
SLIDE 30

MDACC TBI – Lung blocks

  • Lungs fully shielded for 4, 6, 8 fractions
  • Block shadows are aligned on patient in

treatment position

  • Port film (40 MU) taken
  • Blocks adjusted (if necessary) and port

film retaken (if necessary)

  • MU for port film(s) subtracted from

treatment MU

  • Lungs fully shielded for 4, 6, 8 fractions
  • Block shadows are aligned on patient in

treatment position

  • Port film (40 MU) taken
  • Blocks adjusted (if necessary) and port

film retaken (if necessary)

  • MU for port film(s) subtracted from

treatment MU

slide-31
SLIDE 31

MDACC TBI—Lung Blocks

slide-32
SLIDE 32

MDACC TBI—Lung Blocks

slide-33
SLIDE 33

In-Vivo TLD Measurements

slide-34
SLIDE 34

MDACC TBI – Setup Notes

  • Lateral decubitus position, patient lying on

styrofoam (lifts patient off gurney)

  • Scatter plate close to patient
  • Rice bags for neck bolus
  • Laser on calves for AP, on ankle for PA
  • Legs bent to fit patient in light field
  • Lateral decubitus position, patient lying on

styrofoam (lifts patient off gurney)

  • Scatter plate close to patient
  • Rice bags for neck bolus
  • Laser on calves for AP, on ankle for PA
  • Legs bent to fit patient in light field
slide-35
SLIDE 35

TBI dose uniformity

(TLD, RANDO phantom, Therac 20, no bolus)

RANDO slice # 85% 90% 95% 100% 105% 110% 115% 5 10 15 20 25 30 35

midline posterior skin surface anterior skin surface

Neck

Pelvis

slide-36
SLIDE 36

Chair Technique

slide-37
SLIDE 37

SCOT-TBI

  • Chair Technique, AP/PA
  • Beam Energy ≥ 6 MV
  • Dose = 4 x 200 cGy/Fraction
  • Dose to Lung & Kidney = 50 cGy/Fraction
  • Dose Uniformity(Points 1-5): ±10% of

200cGy/fraction

  • Chair Technique, AP/PA
  • Beam Energy ≥ 6 MV
  • Dose = 4 x 200 cGy/Fraction
  • Dose to Lung & Kidney = 50 cGy/Fraction
  • Dose Uniformity(Points 1-5): ±10% of

200cGy/fraction

slide-38
SLIDE 38

Lung and Kidney

SCOT blocks SCOT blocks

Shielding (shaded area) Lung Kidney

If CT alone (no U-sound)

1-1.5 cm 1-1.5 cm 1-1.5 cm 2-2.5 cm 0.5 cm 4 cm 1.5 cm 0.0 cm

slide-39
SLIDE 39

Dose Points

Dose Prescribed: Umbilicus (mid plane) Dose Prescribed: Umbilicus (mid plane) # 1 Head # 6 Hip # 2 Neck # 7 Rt Knee # 3 Rt Shoulder # 8 Rt Ankle # 4

Mid Mediastinum # 9

Rt Lung # 5 Lumbar Spine #10 Rt Kidney

slide-40
SLIDE 40

UTMDACC Division of Radiation Oncology Radiation Physics Department

  • K. Prado, Ph.D., R. Lane, Ph.D.
  • Jun. 16, 2004

MDACC "Chair" Total Body Irradiation Commissioning Varian 21EX SN 2349 (2108)

TBI Geometry

18 MV (or 6 MV)

TBI X Insert Collimator Setting: 40 X 40 Collimator Angle 45 Degrees Gantry Angle: 90 degrees

Instrumentation

PTW N23333 SN 747 Farmer Chamber CNMC 206 SN 3659204 Electrometer

Measurement Phantom(s): Plastic-Water Block 30 x 30 x 30 cm Measurement / Calculation Point: at d

max

Irradiation Geometry

Refrence-Point Distance = 551 - 30 = 521 cm

" Output " is defined at d

max

in full-scatter, 521 cm source-point-distance, 40 x 40 field, gantry 90 , through scattering plate 18 MV:

0.0422

cGy / MU 6 MV: 0.0400 cGy / MU

Patient Support 551 cm to Wall

Plastic-Water Phantom

  • n Chair;

Reference Point at 30 cm from Wall Scattering Plate

Back Wall

slide-41
SLIDE 41

UTMDACC Division of Radiation Oncology Radiation Physics Department

  • K. Prado, Ph.D., R. Lane, Ph.D.

MDACC "Chair" Total Body Irradiation Commissioning Varian 21EX SN 2349 (2108)

TBI Geometry

18 MV (or 6 MV)

TBI X Insert Collimator Setting: 40 X 40 Collimator Angle 45 Degrees Gantry Angle: 90 degrees

Instrumentation

Measurement Phantom(s):

PTW N23333 SN 747 Farmer Chamber

Plastic-Water Block

CNMC 206 SN 3659204 Electrometer

30 x 30 x 30 cm Measurement / Calculation Point: at d

max

"Standard" Setup: 100 cm SSD, d

max, 10 X 10

18 MV 400 MU

79.81 79.83 Average 79.82

6 MV 400 MU

78.05 78.06 Average 78.06 "TBI" Setup: 380 cm SPD, d

max, 40 X 40, scattering plate

18 MV 400 MU

3.37 3.36 Average 3.37

6 MV 400 MU

3.12 3.12 Average 3.12

"Output":

18 MV 0.0422 cGy / MU 6 MV 0.0400 cGy / MU

"Calculation Check" of Output Measurement

SC 40 SP 30 InvSq Trans

SP

Calc Measd Measd/Calc 18 MV

1

1.056 1.047 0.0395 0.975 0.0425 0.0422 0.991

6 MV

2

1.061 1.035 0.0380 0.965 0.0402 0.0400 0.994

Notes: 1 SC and S

P from MUSC 2 All Data MDACC

Output calc:

Dose = Dose @Ext SSD / Dose @ Std Geometry ISQ = [ (100 + dmax) / Ext SSD] 2 Calc = Sc. Sp. ISQ. TF

slide-42
SLIDE 42

Total Body Irradiation (MDACC 'CHAIR') Calculation Worksheet

Patient:

Protocol:

MR Number: 492877

Treatment Date:

Rx:

Total Dose:

450

cGy RX Point: umbilicus Dose per Fraction:

450

cGy per fraction Number of Fractions:

1

Number of Fields:

2 Field: AP TBI

Field Dose:

225

No. Calculation Distance Separation Mid TMR OAF

Output

Dose at Percent Difference Point Off-Axis

(Sep)

Depth

@ Calc Pt @ Calc Pt

  • f CAx

> 10 % ? 1

Head 80 20 10.00 0.892 1.090 0.0411 269.6 119.8% Yes

2

Neck 60 10 5.00 0.976 1.071 0.0441 289.6 128.7% Yes

3

SSN 40 30 15.00 0.809 1.041 0.0355 233.2 103.7% No

4

Chest 20 40 20.00 0.725 1.014 0.0310 203.7 90.5% No

5

Umbilicus 30 15.00 0.809 1.004 0.0343 225.0 100.0% No

6

Pelvis 10 50 25.00 0.642 1.006 0.0272 178.9 79.5% Yes

7

Mid Thigh 30 25 12.50 0.851 1.026 0.0368 241.8 107.5% No

8

Knee 50 10 5.00 0.976 1.057 0.0435 285.6 127.0% Yes

9

Lower Leg 70 8 4.00 0.993 1.083 0.0454 297.8 132.4% Yes

10

Ankle/Foot 90 4 2.00 1.000 1.091 0.0461 302.3 134.4% Yes MU =

6565

TBI Parameters / Equations:

Computed By / Date: Ref Output: 0.0422 cGy/MU Initial Check By / Date: Final Check By / Date: Output

CalcPt = O ref x TMR x OAF

MU = Rx Dose / (Out

umbilicus)

Approved by Attending M.D.:

18 MV X Rays

Computed Cell

TEST

Varian 2108

slide-43
SLIDE 43

Pediatric TBI - Single Fx

slide-44
SLIDE 44

MDACC “Pediatric” TBI: Lung / Kidney Blocks

slide-45
SLIDE 45

MDACC “Pediatric” TBI: Lung / Kidney Blocks

slide-46
SLIDE 46

QA–Annual Calibration

  • Check setup laser
  • Measure beam profile

–ion chamber in air and plastic, compare to previous data

  • Measure PDD in water @ Ext SSD
  • Dose calibration @ Ext SAD, 10 cm depth

–relative to dmax dose at 100 cm SSD, 1010 cm2 field

  • Check setup laser
  • Measure beam profile

–ion chamber in air and plastic, compare to previous data

  • Measure PDD in water @ Ext SSD
  • Dose calibration @ Ext SAD, 10 cm depth

–relative to dmax dose at 100 cm SSD, 1010 cm2 field

slide-47
SLIDE 47

Summary Current MDACC TBI

  • 18 MV, AP-PA positions

– good homogeneity

  • Custom Lung Blocks

– no special compensators needed

  • Uses 4040 (100 cm SAD) TMR data

– measured TMR @ Ext SAD is only slightly

different than standard TMR data – RANDO phantom and in-vivo measurements confirm accurate dose delivery

  • No extra daily or weekly QA needed
  • 18 MV, AP-PA positions

– good homogeneity

  • Custom Lung Blocks

– no special compensators needed

  • Uses 4040 (100 cm SAD) TMR data

– measured TMR @ Ext SAD is only slightly

different than standard TMR data – RANDO phantom and in-vivo measurements confirm accurate dose delivery

  • No extra daily or weekly QA needed
slide-48
SLIDE 48

ACKNOWLEDGEMENTS

  • Melinda Chi
  • Chester Wang
  • Sam Tung
  • Ramesh Tailor
  • Melinda Chi
  • Chester Wang
  • Sam Tung
  • Ramesh Tailor